145 related articles for article (PubMed ID: 10914711)
21. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
[TBL] [Abstract][Full Text] [Related]
23. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
25. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
26. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
27. The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer.
Ferrero JM; Chamorey E; Magné N; Leccia F; Largillier R; Namer M; Milano G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):459-64. PubMed ID: 12451472
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
Fidias P; Supko JG; Martins R; Boral A; Carey R; Grossbard M; Shapiro G; Ostler P; Lucca J; Johnson BE; Skarin A; Lynch TJ
Clin Cancer Res; 2001 Dec; 7(12):3942-9. PubMed ID: 11751486
[TBL] [Abstract][Full Text] [Related]
30. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
Gridelli C; Manegold C; Mali P; Reck M; Portalone L; Castelnau O; Stahel R; Betticher D; Pless M; Pons JT; Aubert D; Burillon JP; Parlier Y; De Marinis F
Eur J Cancer; 2004 Nov; 40(16):2424-31. PubMed ID: 15519515
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.
Freyer G; Delozier T; Lichinister M; Gedouin D; Bougnoux P; His P; Imadalou K; Trillet-Lenoir V
J Clin Oncol; 2003 Jan; 21(1):35-40. PubMed ID: 12506167
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
33. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.
Yang SH; Lin CC; Lin ZZ; Tseng YL; Hong RL
Invest New Drugs; 2012 Feb; 30(1):282-9. PubMed ID: 20809205
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics of vinorelbine.
Levêque D; Jehl F
Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
[TBL] [Abstract][Full Text] [Related]
35. The clinical pharmacokinetics of vinorelbine (Navelbine).
Wargin WA; Lucas VS
Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.
Sorio R; Robieux I; Galligioni E; Freschi A; Colussi AM; Crivellari D; Saracchini S; Monfardini S
Eur J Cancer; 1997 Feb; 33(2):301-3. PubMed ID: 9135505
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample.
Leca FR; Marchiset-Leca D; Galeani A; Noble A; Catalin J
Anticancer Drugs; 1998 Jul; 9(6):503-9. PubMed ID: 9877237
[TBL] [Abstract][Full Text] [Related]
39. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
[TBL] [Abstract][Full Text] [Related]
40. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions.
Cattel L; Recalenda V; Airoldi M; Tagini V; Arpicco S; Brusa P; Bumma C
Farmaco; 2001 Oct; 56(10):779-84. PubMed ID: 11718271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]